Gara Jalqabaatti › Kansara Qara'a Non-Small Cell › Missouri › Kansas City
Qorannoo klinikaalii Kansara Qara'a Non-Small Cell Kansas City, MO keessatti
Qorannoo 31 Kansara Qara'a Non-Small Cell f Kansas City fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Namoota walitti qabaa jiraSadarkaa 3
- St. Lukes Hosp. of Kansas City /ID# 259940, Kansas City
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Namoota walitti qabaa jiraSadarkaa 3
- Truman Medical Center ( Site 0126), Kansas City
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Namoota walitti qabaa jiraSadarkaa 3
- Saint Luke's Hospital of Kansas City, Kansas City
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Namoota walitti qabaa jiraSadarkaa 3
- University Health Truman Medical Center, Kansas City
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- St. Lukes Hospital of Kansas City, Kansas City
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Namoota walitti qabaa jiraSadarkaa 3
- The University of Kansas Cancer Center, Westwood · Miili 5 fagaatti
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 2
- University of Kansas Cancer Center, Westwood · Miili 5 fagaatti
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Namoota walitti qabaa jiraSadarkaa 2
- Truman Medical Ctr West, Kansas City
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Research Site, Westwood · Miili 5 fagaatti
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
Namoota walitti qabaa jiraSadarkaa 3
- Saint Luke's Hospital of Kansas City, Kansas City
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Namoota walitti qabaa jiraSadarkaa 3
- Research Site, Kansas City
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Namoota walitti qabaa jiraSadarkaa 3
- Local Institution - 0498, Kansas City
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Namoota walitti qabaa jiraSadarkaa 3
- Research Site, Kansas City
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Namoota walitti qabaa jiraSadarkaa 3
- Clinical Study Site, Kansas City
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- University of Kansas, Westwood · Miili 5 fagaatti
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Namoota walitti qabaa jiraSadarkaa 2/3
- University of Kansas Medical Center /ID# 263196, Westwood · Miili 5 fagaatti
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Namoota walitti qabaa jiraSadarkaa 1
- Saint Luke's Cancer Institute, Kansas City
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 3
- The University of Kansas Cancer Center - Westwood, Westwood · Miili 5 fagaatti
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Namoota walitti qabaa jiraSadarkaa 3
- University of Kansas Cancer Center - North, Kansas City
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Namoota walitti qabaa jiraSadarkaa 1/2
- University of Kansas Medical Center (KUMC), Westwood · Miili 5 fagaatti
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- MidAmerica Cancer Care, Kansas City
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- The University of Kansas Cancer Center - Westwood, Westwood · Miili 5 fagaatti
- University of Kansas Cancer Center, Westwood · Miili 5 fagaatti
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Namoota walitti qabaa jiraSadarkaa 3
- University of Kansas Cancer Center - North, Kansas City
- University of Kansas Cancer Center, Westwood · Miili 5 fagaatti
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 1/2
- The University of Kansas Cancer Center, Westwood · Miili 5 fagaatti
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Namoota walitti qabaa jiraSadarkaa 2
- University Health Truman Medical Center, Kansas City
- University of Kansas Cancer Center - Briarcliff, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- fi 1 dabalataa
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Research Site, Kansas City
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Namoota walitti qabaa jiraSadarkaa 2
- University Health Truman Medical Center, Kansas City
- University of Kansas Cancer Center - Briarcliff, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- fi 1 dabalataa
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Namoota walitti qabaa jiraSadarkaa 2/3
- University Health Truman Medical Center, Kansas City
- University of Kansas Cancer Center - Briarcliff, Kansas City
- Kansas City Veterans Affairs Medical Center, Kansas City
- fi 2 dabalataa
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Namoota walitti qabaa jiraSadarkaa 2
- University Health Truman Medical Center, Kansas City
- University of Kansas Cancer Center - Briarcliff, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- fi 1 dabalataa
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Namoota walitti qabaa jiraQorannoo ilaalaa
- University Health Truman Medical Center, Kansas City
- University of Kansas Cancer Center - Briarcliff, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- fi 1 dabalataa
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Namoota walitti qabaa jiraQorannoo ilaalaa
- Massive Bio SYNERGY-AI site, Kansas City
Qorannoo Kansara Qara'a Non-Small Cell magaalota biroo keessatti
- Houston, TXQorannoo 145
- New York City, NYQorannoo 121
- Arlington, VAQorannoo 104
- Nashville, TNQorannoo 97
- Boston, MAQorannoo 90
- Los Angeles, CAQorannoo 87
- St. Louis, MOQorannoo 73
- Chicago, ILQorannoo 61
- Baltimore, MDQorannoo 60
- San Antonio, TXQorannoo 59
- Columbus, OHQorannoo 57
- Washington, DCQorannoo 55
Qorannoo biroo Kansas City keessatti
- Saree OljooQorannoo 34
- Cufama OnneeQorannoo 25
- Saree (Gosoota Hunda)Qorannoo 21
- Dhibee QaraQorannoo 19
- Kansarii ColorectalQorannoo 16
- Kansara MetastatikiiQorannoo 15
- Leukemia Myeloidii HamaaQorannoo 15
- Kansarii ProstateQorannoo 14
- Kansarii OvariiQorannoo 11
- ObesityQorannoo 11
- Sukkaraa Gosa 2Qorannoo 11
- Dhibee Onneessaa fi DhiigaQorannoo 11
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.